2% by the introduction of gonadotrophin-releasing hormone (GnRH) agonists into stimulation protocols for assisted repro- 4 To whom correspondence should be addressed duction techniques (Porter et al., 1984;  Stanger and Yovich, A total of 346 women with normal ovulatory function Wildt et al., 1986) . The long agonistic protocol, which was stimulated with human menopausal gonadotrophins aims to achieve complete desensitization of GnRH receptors (HMG) to attain ovarian stimulation for IVF or intracytobefore the start of HMG administration, has become the 'gold plasmic sperm injection (ICSI). Stimulation with HMG standard' for ovarian stimulation in assisted reproduction started on cycle day 2 or 3. After 6 days of stimulation, techniques (Biljan and Tan, 1998) . Recently, the GnRH antagCetrorelix in its minimum effective multiple dose of 0. 25 onist Cetrorelix (ASTA-Medica AG, Frankfurt/Main, mg/day, was administered daily until induction of ovulation.
Germany) has been investigated for ovarian stimulation in In total, 333 patients (96.2%) reached the day of HCG assisted reproduction techniques. Cetrorelix has proved to be administration, and 324 (93.6%) underwent oocyte reliable in preventing the onset of premature luteinizing horretrieval. A mean of 25.2 ampoules of HMG was applied mone (LH) surges during HMG stimulation for assisted reprofor a mean of 10.4 days. Cetrorelix was administered for duction techniques, as well by daily injections from 5 or 6 a mean time lapse of 5.7 days. The mean normal fertilization days of stimulation onwards as by a single injection on rate was 60% in the IVF group and 59% in the ICSI stimulation day 7 (Diedrich et al., 1994; Olivennes et al., group . Seventy pregnancies were attained, reflecting an Felberbaum et al., 1995 Felberbaum et al., , 1996 , ongoing clinical pregnancy rate of 24% per transfer. . Pregnancy rates of about 30% per transfer reported ongoing clinical implantation rate was 11.4%. Only three seemed to be very promising (Albano et al., 1997) . However, cases of raised luteinizing hormone (LH) (≥10 IU/l) with reports regarding the possibility of lowering the amount of increased progesterone secretion (≥1 ng/ml) were observed HMG ampoules to obtain satisfactory follicular maturation by after initiation of Cetrorelix administration, reflecting an using GnRH antagonists instead of a desensitizing protocol incidence of premature luteinization of 0.9%. The abortion have been contradictory (Albano et al., 1996 ; Felberbaum rate was 17%. The incidence of severe ovarian hyperstimu et al., 1996) . No data regarding the incidence of serious ovarian lation syndrome (World Health Organization grade III) hyperstimulation syndrome (OHSS) under these treatment was as low as 0.6%. modalities have been available until now. Overall, there was Key words: Cetrorelix/gonadotrophin-releasing hormone antagclearly a need to obtain more data regarding efficacy and onists/human menopausal gonadotrophins/ovarian stimulation safety aspects of this new therapeutic approach to ovarian stimulation for assisted reproduction techniques. This report details a prospective uncontrolled study including 346 patients treated with Cetrorelix in its minimum effective dose of 0.25 *Prof. Dr K.H.R.Diedrich and Dr med. R.E.Felberbaum, Lübeck, mg/day, according to the multiple dose administration protocol.
LH rise (LH ജ10 IU/l and progesterone ജ1 ng/ml) before HMG day were treated in accordance with the same schedule.
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To proceed with the administration of 10 000 IU of HCG GmbH), the following prerequisites had to be fulfilled: at least one follicle with a diameter of ജ20 mm or an oestradiol concentration ITT ϭ intention to treat.
ജ1200 pg/ml. Luteal phase support was given according to the centre's rules regarding start, duration, medication and dosage. The protocol allowed Statistical methods Study Group-participated in this study, as outlined in Table I .
All statistical evaluations and analyses were performed using SAS™ The infertility could be treated by ovarian stimulation for IVF or 6.09 (SAS Institute Inc., Cary, NC, USA). The primary aim of the intracytoplasmic sperm injection (ICSI), as shown in Table II . The present study was to estimate the response rate defined as successful women had to be between 18 and 39 years of age, with normal ovarian stimulation, the number of patients reaching the day of HCG, menstrual cycles of range 24-35 days, and an intra-individual variation the rate of patients with oocyte retrieval, embryo transfers and of Ϯ 3 days. The mean age of the patients was 32 Ϯ 4 years, and pregnancies, as well as to assess serious adverse events. As a response the mean body weight 62 Ϯ 10 kg. No more than three IVF procedures rate of at least 95% was to be expected in order to obtain lower oneshould have taken place in the past. A normal uterus and at least one sided 95% confidence limits (CL) of 92.5%, a sample size of 319 functioning ovary were basic requirements.
patients was required. Assuming a rate of about 6% for non-evaluable All patients started treatment with two ampoules of HMG and patients, the inclusion of 340 patients seemed to be appropriate. A remained on that dose for 5 days. Thereafter, the stimulation procedure sample size of 340 patients and a pregnancy rate of about 20% would with respect to the amount of HMG administered per day was handled lead to about 65 babies being delivered. For this reason at least one variably in the separate centres.
adverse experience would have been observed with 95% probability Cetrorelix (ASTA-Medica AG, Frankfurt/Main, Germany) was to given an assumed incidence of ജ4.5%. One-sided 95% lower CL were be injected once daily in doses of 0.25 mg s.c. into the lower calculated according to Clopper-Pearson for the efficacy parameters. abdominal wall, starting from day 6 of treatment with HMG (Humegon ® ; Organon, Oss, The Netherlands/Menogon ® , Ferring GmbH, Kiel, Germany) of the ovarian stimulation cycle up to
Results
and including the day of human chorionic gonadotrophin (HCG) After having obtained fully informed consent, 352 patients administration. Although Cetrorelix should always have been initiated were screened for enrolment into the study and 346 patients on stimulation day 6, some centres started the administration on day started HMG stimulation and concomitant Cetrorelix treatment.
5 in some patients. This was considered to be a minor protocol violation and did not lead to patients' exclusion. In case, of premature Six patients were screened, but received neither HMG nor gonadotrophin-releasing hormone antagonist treatment (Cetrorelix, 0.25 mg/day). All hormone analyses were performed in a central laboratory. n ϭ number of patients with serum samples available for hormone analysis. Vertical line indicates missing HMG and safety criteria, as well as with respect to compliance.
b Data post human menopausal gonadotrophin (HMG) day 6 are missing
As expected, the HMG stimulation had an important impact from one patient. c According to protocol definition: LH ജ10 IU/l and progesterone ജ1 ng/ml. on hormone concentrations. FSH rose continuously to a mean concentration of 13.8 mIU/ml (day of HCG administration) as long as the HMG treatment continued. Concentrations of oestradiol increased to a mean of 1544 pg/ml (morning value; the case of the first patient, no central laboratory analysis was available. However, this patient was considered to be one of central laboratory) on the day of HCG injection.
LH concentrations were clearly suppressed during the entire the major protocol violators, as the FSH concentration at HMG day 1 was Ͼ12 mIU/ml, and HMG started on day 4 of the stimulation period (Figure 1) . The median evening value on the day of HCG injection was 1.0 IU/l (evening value, central cycle instead of day 2 or 3. Finally, the cycle was cancelled in this case as the woman refused to continue ovarian stimulalaboratory).
The median duration of Cetrorelix treatment was 5 days tion. In the case of the second patient, the response to ovarian stimulation was very poor, and although progesterone did not (mean 5.7 days; range 1-15 days). Among 346 cycles, none had to be cancelled because of allergic, anaphylactoid, local reach a concentration of 1 ng/ml, the cycle was cancelled because LH values were above 24 IU/l. hypersensitivity or other adverse reactions of the patient.
A mean of 25.2 ampoules (median 23 ampoules) of HMG Premature rises of LH were given for a mean of 10.4 days. HMG was administered in all patients for a minimum of 6 and up to a maximum of The incidence of premature LH rises above 10 IU/l during stimulation, and premature luteinization of the follicles as 19 days.
indicated by progesterone values above 1 ng/ml, were analysed Primary parameters of efficacy once by the results from the local laboratory, and once by the results from the central laboratory (Tables III and IV) . Among 346 patients treated according to the described treatment modalities, 333 fulfilled the criteria for administration of Generally, the central laboratory provided slightly lower LH values. Including HMG day 6 for analysis led to an incidence HCG to induce final oocyte maturation. This reflected a 96.2% efficacy rate in respect of the primary parameter of success of LH rises as defined by the study protocol (LH ജ10 IU/l and progesterone ജ1 ng/ml) of 3.5% with 95% CL of 5.6% with a lower 95% CL of 94.1%.
Two of the patients without HCG administration showed a according to local laboratory values, and 1.8% (95% CL ϭ 3.5%) according to central laboratory data. This incidence rise in LH, one on HMG day 7 and one on HMG day 13. In dropped after having started Cetrorelix administration on HMG 1993). The fertilization rate, defined as the number of fertilized day 6 to as low as 2.9% (95% CL ϭ 4.9%) according to local (two pronuclear, 2PN) oocytes per inseminated (IVF) or laboratory values and 0.9% (95% CL ϭ 2.3%) according to injected (ICSI) metaphase II oocyte, was nearly the same for central laboratory data. both methods of fertilization, which means 60% for IVF and HCG was administered in 12 out of 13 cases with elevations 59% for ICSI per cumulus-oocyte complex. In total, 149 of LH above 10 IU/l without rising concentrations of progesterpatients were submitted to the IVF procedure, while metaphase one. Oocyte retrieval and subsequent fertilization were per-II oocytes of 162 patients were the subject of the microinjection formed as planned in eight of these patients; cumulus-oocyte method, and 11 patients were submitted to both procedures complexes were obtained in seven of these cases. The fertiliza- (Table V) . tion led to embryos of good to excellent quality in six of the A total of 2971 cumulus-oocyte complexes was retrieved, eight cases, and to embryos of fair quality in two cases. The and these led to 1253 embryos; 34% of these embryos were treatment cycle of one of these patients led, after replacement of excellent quality according to microscopical morphological of two embryos of excellent quality, to a viable ongoing criteria, 46% were of good quality, and 19% were of fair clinical pregnancy.
quality (Staessen et al., 1989) . The replacement of a mean of On HMG day 6, the frequency of patients with follicles of 2.7 embryos per transfer in 299 transfers induced 70 clinical a given size was distributed as follows: 80% of patients had pregnancies, as assessed by transvaginal sonography docufollicles of 11-14 mm, 33% of 15-19 mm, and 3% large menting fetal heart activity. Thus, the clinical pregnancy rate follicles (ജ20 mm). This turned on the day of HCG injection was 24% per transfer. The ongoing clinical implantation rate when 72% of patients had follicles of 11-14 mm, 96% of 15-was 11.4 Ϯ 22.6% when calculated by the number of embryos 19 mm, and 89% had large follicles (ജ20 mm). On the day seen by transvaginal sonography on days 21-24 after embryo of HCG administration, 10.1 follicles were seen on average, transfer divided by the total number of embryos replaced. This and the mean number of follicles with a diameter ജ20 mm ongoing clinical implantation rate may reflect incomplete data, was 2.4.
as the number of gestational sacs in cases of early pregnancy loss or ectopic pregnancies remains unknown. Twelve abortions Fertilization rate, quality of embryos and pregnancy rate were observed (abortion rate 17%). Among a total of 324 patients with oocyte retrieval, 2971 cumulus-oocyte complexes were obtained. No oocyte was Adverse drug reaction retrieved from two patients. The mean percentage of mature Injection site reactions were seen in only three patients (0.9%), oocytes, as assessed according to microscopic criteria was while one case of hot flushes was reported and attributed to 63.7% for patients submitted to IVF, while the mean percentage the use of the GnRH antagonist Cetrorelix. et al., 1989) . Other authors have reported reduced amounts 0.6% (2/346).
of gonadotrophins of about 28 ampoules per cycle using recombinant FSH (Out et al., 1996 (Out et al., , 1997 . The results of a Discussion large series is awaited to show whether a combination of GnRH antagonists with recombinant FSH will lead to a further Although the clinical development of early generation GnRH antagonists was hampered by their ability to initiate systemic reduction in gonadotrophins to be used for ovarian stimulation.
The number and quality of recovered oocytes, the percentage allergic as well as severe local hypersensitivity reactions due to mast cell degranulation and histamine release, these problems of metaphase II oocytes to be used for ICSI, and fertilization rates after ICSI or IVF must be considered absolutely normal have been completely resolved by the introduction of GnRH antagonists such as Cetrorelix (Hahn et al., 1985; as expected after normal oocyte maturation for assisted reproduction techniques Ubaldi et al., 1995 Ubaldi et al., ). et al., 1995 Schally and Comaru-Schally, 1997) . On the basis of this extremely important observation, it has been possible A clinical pregnancy rate of 24% per transfer is an acceptable result, and within the estimated limits of an open nonto introduce Cetrorelix successfully into protocols for ovarian stimulation (Diedrich et al., 1994; Olivennes et al., 1995;  comparative study. These results are even higher than that reported in available European national IVF registers (French Felberbaum et al., 1996; Albano et al., 1997) . Daily midcycle administrations with concomitant HMG stimulation and single IVF Registry, 1995; Deech, 1996; Deutsches IVF-Register, 1997) . However, this clinical pregnancy rate of 24% may be dose administration at day 7 of HMG stimulation were each able to reliably prevent the onset of premature LH surges.
influenced by the fact that the population of patients recruited for this study excluded difficult cases such as patients suffering Subsequent phase II dose-finding studies defined 0.25 mg of Cetrorelix per day as the minimum effective dose for the from polycystic ovarian disease, known low responders, or women aged more than 39 years. prevention of premature ovulation induced by premature LH surges, according to the multiple dose protocol (Albano et al., It is reassuring to observe that, when using Cetrorelix, the percentage of babies born per embryo replaced was 10%. 1996 Felberbaum et al., 1996) . Using only 0.1 mg of Cetrorelix per day according to this administration scheme did An incidence of 0.6% of severe OHSS (WHO grade III) leading to hospitalization of the patient is low in comparison not prevent the onset of premature rises of LH (Albano et al., 1997) . However, to date the number of treated patients using with the incidence (6.6%) reported after long-protocol agonist treatment (Ron-El et al., 1991) . Taking into account all the 0.25 mg of Cetrorelix has been very few, and consequently experience with this new compound is limited. For this reason, complications and risks that severe OHSS implies for the patient (such as thrombosis, embolism, putative myocardial a large phase III multicentre trial was initiated. This study evaluated the safety and efficacy of Cetrorelix at its minimum infarction and even occasional death), this suggests a major improvement in safety aspects. It is possible that modifications effective dose of 0.25 mg/day according to the multiple-dose protocol, and was the first to do so for a GnRH antagonist in of the stimulation procedures, incorporating softer agents such as clomiphene citrate, may allow this severe, purely iatrogenic ovarian stimulation. In particular, no such database on daily hormonal measurements during stimulation therapy has been disease within assisted reproduction treatment to be abolished (Diedrich and Felberbaum, 1998) . reported to date. Patient compliance was excellent, and no patient had to be excluded due to allergic or hypersensitivity As yet, it may be too early to predict an end of the agonist era for ovarian stimulation, and these agents will likely retain reactions, thus demonstrating that clinically relevant histamine release by this compound was avoided. In total, 333 patients their importance in special indications such as endometriosis patients in whom assisted reproduction treatment is envisaged. showed satisfactory follicular development leading to administration of HCG for final oocyte maturation. In 324 patients, However, if confirmation is obtained in large comparative studies, there may be clear advantages of antagonist cooocyte retrieval was undertaken. After having started Cetrorelix treatment, the incidence of premature LH rises followed by treatment with gonadotrophins in ovarian stimulation with regard to the patient's comfort, and reductions in treatment premature luteinization of the growing follicles was 0.9%. This was within the range to be expected after GnRH agonist duration, medication and costs, while achieving the same range of therapeutic outcome. administration for assisted reproduction techniques, according In summary, this study has demonstrated the efficacy and to the so-called 'long' protocol (Smitz et al., 1992) . By safety of Cetrorelix in ovarian stimulation with HMG for IVF, using Cetrorelix, follicular distribution at the day of HCG with a pregnancy rate of 24% per embryo transfer being administration reflected a fairly homogeneous follicular develsatisfactory. The incidence of severe OHSS grade III as opment with only few small and intermediate follicles. It has low as 0.6% indicated that Cetrorelix makes an important been documented that the presence of several intermediate and contribution to the safety of the treatment. small follicles at the day of HCG administration may increase the risk of OHSS (Ron El et al., 1991) . A mean of 10.2 follicles on the day of HCG treatment seems to be almost
